Neuland Laboratories Ltd.

NSE: NEULANDLAB | BSE: 524558 | ISIN: INE794A01010 | Industry: Pharmaceuticals
| Expensive Performer
12245.0000 34.00 (0.28%)
NSE Jun 20, 2025 15:31 PM
Volume: 56,880
 

12245.00
0.28%

Neuland Laboratories Ltd Q2FY17 Result Review

BOB Capital Markets Ltd.
Amalgamation Scheme: The scheme involves issue of fresh equity shares by NLL to NHSPL and NPRPL which would increase NLL's equity by 25.6%. Promoter holding would change from 51.68% to 41.29 % post-merger. This would likely come into effect from Q2FY18. The amalgamation is aimed at building stronger business and financials, obtain tax benefits by clubbing R&D; services required for CMS business & better operational convenience. Going forward, we expect NLL to enjoy high margins led by strong...
Number of MF schemes increased from 16 to 23 in Mar 2025 qtr.
More from Neuland Laboratories Ltd.
Recommended